BACKGROUND: Clinical trials in ischemic patients showed the safety and benefit of autologous bone marrow progenitor cell transplantation. Non-bone marrow progenitor cells with proangiogenic capacities have been described, yet they remain clinically unexploited owing to their scarcity, difficulty of access, and low ex vivo expansibility. We investigated the presence, antigenic profile, expansion capacity, and proangiogenic potential of progenitor cells from the saphenous vein of patients undergoing coronary artery bypass surgery. METHODS AND RESULTS: CD34-positive cells, negative for the endothelial marker von Willebrand factor, were localized around adventitial vasa vasorum. After dissection of the vein from surrounding tissues and enzymatic digestion, CD34-positive/CD31-negative cells were isolated by selective culture, immunomagnetic beads, or fluorescence-assisted cell sorting. In the presence of serum, CD34-positive/CD31-negative cells gave rise to a highly proliferative population that expressed pericyte/mesenchymal antigens together with the stem cell marker Sox2 and showed clonogenic and multilineage differentiation capacities. We called this population "saphenous vein-derived progenitor cells" (SVPs). In culture, SVPs integrated into networks formed by endothelial cells and supported angiogenesis through paracrine mechanisms. Reciprocally, endothelial cell-released factors facilitated SVP migration. These interactive responses were inhibited by Tie-2 or platelet-derived growth factor-BB blockade. Intramuscular injection of SVPs in ischemic limbs of immunodeficient mice improved neovascularization and blood flow recovery. At 14 days after transplantation, proliferating SVPs were still detectable in the recipient muscles, where they established N-cadherin-mediated physical contact with the capillary endothelium. CONCLUSIONS: SVPs generated from human vein CD34-positive/CD31-negative progenitor cells might represent a new therapeutic tool for angiogenic therapy in ischemic patients.
BACKGROUND: Clinical trials in ischemicpatients showed the safety and benefit of autologous bone marrow progenitor cell transplantation. Non-bone marrow progenitor cells with proangiogenic capacities have been described, yet they remain clinically unexploited owing to their scarcity, difficulty of access, and low ex vivo expansibility. We investigated the presence, antigenic profile, expansion capacity, and proangiogenic potential of progenitor cells from the saphenous vein of patients undergoing coronary artery bypass surgery. METHODS AND RESULTS:CD34-positive cells, negative for the endothelial marker von Willebrand factor, were localized around adventitial vasa vasorum. After dissection of the vein from surrounding tissues and enzymatic digestion, CD34-positive/CD31-negative cells were isolated by selective culture, immunomagnetic beads, or fluorescence-assisted cell sorting. In the presence of serum, CD34-positive/CD31-negative cells gave rise to a highly proliferative population that expressed pericyte/mesenchymal antigens together with the stem cell marker Sox2 and showed clonogenic and multilineage differentiation capacities. We called this population "saphenous vein-derived progenitor cells" (SVPs). In culture, SVPs integrated into networks formed by endothelial cells and supported angiogenesis through paracrine mechanisms. Reciprocally, endothelial cell-released factors facilitated SVP migration. These interactive responses were inhibited by Tie-2 or platelet-derived growth factor-BB blockade. Intramuscular injection of SVPs in ischemic limbs of immunodeficientmice improved neovascularization and blood flow recovery. At 14 days after transplantation, proliferating SVPs were still detectable in the recipient muscles, where they established N-cadherin-mediated physical contact with the capillary endothelium. CONCLUSIONS:SVPs generated from human vein CD34-positive/CD31-negative progenitor cells might represent a new therapeutic tool for angiogenic therapy in ischemicpatients.
Authors: C Farrington-Rock; N J Crofts; M J Doherty; B A Ashton; C Griffin-Jones; A E Canfield Journal: Circulation Date: 2004-10-04 Impact factor: 29.690
Authors: Jamie Y Jeremy; Pat Gadsdon; Nilima Shukla; Vikram Vijayan; Marcella Wyatt; Andrew C Newby; Gianni D Angelini Journal: Biomaterials Date: 2006-11-17 Impact factor: 12.479
Authors: C Emanueli; A Minasi; A Zacheo; J Chao; L Chao; M B Salis; S Straino; M G Tozzi; R Smith; L Gaspa; G Bianchini; F Stillo; M C Capogrossi; P Madeddu Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: C Kalka; H Masuda; T Takahashi; W M Kalka-Moll; M Silver; M Kearney; T Li; J M Isner; T Asahara Journal: Proc Natl Acad Sci U S A Date: 2000-03-28 Impact factor: 11.205
Authors: Peter J Psaltis; Adriana Harbuzariu; Sinny Delacroix; Eric W Holroyd; Robert D Simari Journal: J Cardiovasc Transl Res Date: 2010-11-30 Impact factor: 4.132
Authors: Mark W Majesky; Xiu Rong Dong; Virginia Hoglund; Gunter Daum; William M Mahoney Journal: Cells Tissues Organs Date: 2011-10-14 Impact factor: 2.481
Authors: Richard D Kenagy; Mete Civelek; Shinsuke Kikuchi; Lihua Chen; Anthony Grieff; Michael Sobel; Aldons J Lusis; Alexander W Clowes Journal: J Vasc Surg Date: 2015-04-30 Impact factor: 4.268
Authors: Paul Pang; Molly Abbott; Steven L Chang; Malyun Abdi; Nikita Chauhan; Murti Mistri; Joshua Ghofrani; Quynh-Anh Fucci; Colleen Walker; Corey Leonardi; Samuel Grady; Arvin Halim; Ryan Hoffman; Tzongshi Lu; Huixia Cao; Stefan G Tullius; Sayeed Malek; Sanjaya Kumar; Graeme Steele; Adam Kibel; Benjamin S Freedman; Sushrut S Waikar; Andrew M Siedlecki Journal: Kidney Int Date: 2016-09-29 Impact factor: 10.612